Although limited by a small sample size, increases in PD-L1 in the TME were observed at a higher magnitude in patients with SD relative to patients with progressive disease, and baseline levels ranged from 0% to 20% positivity in tumor cells in the 4 patients with clinical benefit compared with no expression in most patients with progressive disease (Supplementary Figure S5). The gene discussed is CD274; the disease is neoplasm.